Shares of Medpace Holdings Inc (NASDAQ:MEDP) have been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $74.67.
A number of research analysts have recently weighed in on the company. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a report on Friday, October 4th. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday. ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group raised their target price on Medpace from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Tuesday, July 30th. Finally, SunTrust Banks raised their target price on Medpace to $85.00 and gave the company a “buy” rating in a report on Wednesday, July 31st.
Shares of NASDAQ:MEDP opened at $78.74 on Monday. The business’s 50 day simple moving average is $82.11 and its two-hundred day simple moving average is $67.00. The firm has a market cap of $2.83 billion, a P/E ratio of 30.40, a PEG ratio of 2.17 and a beta of 1.55. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.66 and a current ratio of 0.66. Medpace has a 52-week low of $45.88 and a 52-week high of $86.71.
Several hedge funds have recently bought and sold shares of MEDP. Pearl River Capital LLC bought a new position in shares of Medpace in the second quarter valued at approximately $27,000. FTB Advisors Inc. lifted its holdings in Medpace by 171.8% during the second quarter. FTB Advisors Inc. now owns 579 shares of the company’s stock worth $37,000 after acquiring an additional 366 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Medpace by 53.9% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after acquiring an additional 212 shares during the period. Advisor Group Inc. lifted its holdings in Medpace by 18.7% during the second quarter. Advisor Group Inc. now owns 1,462 shares of the company’s stock worth $95,000 after acquiring an additional 230 shares during the period. Finally, Marshall Wace LLP bought a new stake in Medpace during the first quarter worth $99,000. Institutional investors own 85.86% of the company’s stock.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.